• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Jury clears ex-NFL player Gault of purposely defrauding investors

Jury clears ex-NFL player Gault of purposely defrauding investors

March 19, 2015 By MassDevice Contributors Network

Jury clears ex-NFL player Gault of purposely defrauding investors

(Reuters) — A California jury yesterday cleared former Chicago Bears wide receiver Willie Gault of intentionally defrauding investors in a scheme to inflate the price of stock in the heart-monitoring device company Heart Tronics.

The jury’s verdict found Gault, 54, not liable on 4 serious civil fraud charges, including intent to defraud and aiding and abetting fraud.

The jury did find he was liable for 3 other less serious charges, including charges that he violated provisions in the 2002 Sarbanes-Oxley law by filing false certifications in connection with the company’s financial statements.

"Mr. Gault entered the courtroom today with the shroud of serious securities fraud violations hanging over his head, and he exited the courtroom cleared of any serious misconduct and with the equivalent of a securities parking ticket," said his attorney George B. Newhouse Jr., a partner at Dentons.

The verdict comes more than 3 years after the U.S. Securities and Exchange Commission first filed its case against Gault, who previously served as Heart Tronics’ co-CEO, and several other former company executives.

The SEC’s case centered primarily on the actions of Mitchell Stein, the company’s outside counsel, whom the SEC alleged was orchestrating fictitious sales orders for the company’s products to pump up the stock price, selling the shares without disclosing it, and using the proceeds to fund a lavish lifestyle.

Stein was convicted of securities fraud in 2013 in a parallel criminal case, and was later sentenced to 17 years in prison.

The SEC had claimed that Stein brought in Gault as a figurehead of the company to take advantage of his celebrity status and make Heart Tronics seem successful.

Gault played 11 season in the National Football League, winning the Super Bowl with the Chicago Bears in 1985. He was also a member of the U.S. Olympic team that boycotted the 1980 Moscow Games.

The SEC said that Gault, as well as the company’s former CEO J. Rowland Perkins II, failed to question Stein’s conduct and did not meet their fiduciary duties to shareholders.

Last fall, Perkins settled charges that he had signed and certified three quarterly reports with materially false statements about the company’s sale orders, and agreed to pay a $42,500 penalty. He did not admit nor deny the allegations.

Andrew Ceresney, the head of the SEC’s enforcement division, said yesterday that the agency is "pleased" with the verdict in Gault’s case.

"As proved at trial, as CEO of a public company, Willie Gault filed false certifications with the SEC and knowingly circumvented the company’s internal controls," he said in a statement.

Filed Under: Legal News, News Well, Patient Monitoring Tagged With: Heart Tronics, Securities & Exchange Commission (SEC), Signalife

More recent news

  • Cooper Companies continues to see activist pressure to sell divisions, replace CEO
  • Cordis earns FDA nod for Selution SLR drug-eluting balloon
  • Siemens Healthineers links with Novo to advance liver fibrosis blood test
  • GE HealthCare rolls out AI software for predicting care bottlenecks
  • Wandercraft’s self-balancing Eve exoskeleton begins US launch

Primary Sidebar

Cart

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy